Monk, B. J., Kauderer, J. T., Moxley, K. M., Bonebrake, A. J., Dewdney, S. B., Secord, A. A., . . . Aghajanian, C. (2018). A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecologic oncology, 151(3), 422-427. https://doi.org/10.1016/j.ygyno.2018.10.001
Chicago-Zitierstil (17. Ausg.)Monk, Bradley J., James T. Kauderer, Katherine M. Moxley, Albert J. Bonebrake, Summer B. Dewdney, Angeles Alvarez Secord, Frederick R. Ueland, Carolyn M. Johnston, und Carol Aghajanian. "A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: An NRG Oncology/gynecologic Oncology Group Study." Gynecologic Oncology 151, no. 3 (2018): 422-427. https://doi.org/10.1016/j.ygyno.2018.10.001.
MLA-Zitierstil (9. Ausg.)Monk, Bradley J., et al. "A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: An NRG Oncology/gynecologic Oncology Group Study." Gynecologic Oncology, vol. 151, no. 3, 2018, pp. 422-427, https://doi.org/10.1016/j.ygyno.2018.10.001.